Cancer Support Group

Sunday, Nov 17th

Last update:06:42:40 AM GMT

Home News and Update Year 2010 Gene Set Shows Which Patients Benefit From Chemotherapy After Surgery

Gene Set Shows Which Patients Benefit From Chemotherapy After Surgery

DNA India
08 September 2010
Washington, DC USA

Scientists have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery.

The study, advances the 2005 findings of the NCIC Clinical Trials Group study JBR.10, conducted in collaboration with the US National Cancer Institute.

The JBR.10 findings showed significant survival benefit from the anti-cancer drugs vinorelbine and cisplatin in patients with early–stage (stage I and II) non–small cell lung cancer whose tumors had been surgically removed.

Principal investigator Dr. Ming Tsao, pathologist at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN), and Professor of Laboratory Medicine and Pathobiology at the University of Toronto research team and collaborators at NCIC Clinical Trials Group at Queen’s University performed a genetic analysis of tumor tissue from 133 of the 482 patients from the JBR.10 study who had banked frozen tumor samples.

The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).

They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease experienced the greatest benefit from chemotherapy – with a 67 percent reduction in the risk of death – while chemotherapy did not reduce the risk of death in patients designated as low risk.

While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao’s study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post–operative chemotherapy.

The study has been published online in the Journal of Clinical Oncology (JCO 64325).

Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.

Suggestions

This is YOUR sites, so if you have suggestions or feedback on how we can improve it for you, please let us know! We do our best to keep up!

Make a Suggestion
Manthan Award

Link to Aarogya

aarogya logo
NASSCOM Award